Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel Free SANA Stock Alerts

Sana Biotechnology (SANA) Financials

Sana Biotechnology logo
$3.20 +0.07 (+2.24%)
Closing price 04:00 PM Eastern
Extended Trading
$3.20 +0.00 (+0.06%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Sana Biotechnology

Annual Income Statements for Sana Biotechnology

This table shows Sana Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -131 -285 -356 -269 -283 -267 -244
Consolidated Net Income / (Loss)		 -131 -285 -356 -269 -283 -267 -244
Net Income / (Loss) Continuing Operations		 -131 -285 -356 -269 -283 -267 -244
Total Pre-Tax Income 		-138 -285 -356 -269 -283 -267 -246
Total Operating Income		 -141 -286 -357 -273 -293 -273 -250
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 141 286 357 273 293 273 250
Selling, General & Admin Expense		 22 28 50 72 73 64 44
Research & Development Expense		 119 258 306 201 213 207 161
Impairment Charge		 - - - - 7.01 1.89 45
Total Other Income / (Expense), net		 2.83 0.84 0.98 3.09 9.89 5.96 3.85
Interest & Investment Income		 2.86 0.75 0.68 3.76 9.94 10 3.85
Other Gains / (Losses), net		 - - - - - - 2.31
Basic Earnings per Share		 ($26.68) ($21.92) ($2.14) ($1.43) ($1.46) ($1.16) ($0.96)
Weighted Average Basic Shares Outstanding		 4.90M 13.01M 166.43M 188.34M 194.54M 230.89M 253.23M
Diluted Earnings per Share		 ($26.68) ($21.92) ($2.14) ($1.43) ($1.46) ($1.16) ($0.96)
Weighted Average Diluted Shares Outstanding		 4.90M 13.01M 166.43M 188.34M 194.54M 230.89M 253.23M
Weighted Average Basic & Diluted Shares Outstanding		 4.90M 13.01M 166.43M 191.36M 220.45M 225.02M 266.87M

Quarterly Income Statements for Sana Biotechnology

This table shows Sana Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47 -64
Consolidated Net Income / (Loss)		 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47 -64
Net Income / (Loss) Continuing Operations		 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47 -64
Total Pre-Tax Income 		-88 -108 -50 -60 -49 -49 -94 -42 -61 -47 -64
Total Operating Income		 -91 -111 -49 -62 -51 -51 -95 -44 -61 -49 -65
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 91 111 49 62 51 51 95 44 61 49 65
Selling, General & Admin Expense		 21 16 16 14 17 11 10 10 12 11 11
Research & Development Expense		 70 94 33 48 34 39 40 33 49 37 55
Impairment Charge		 - - 0.00 0.00 - 0.00 45 0.00 - 0.00 0.00
Total Other Income / (Expense), net		 2.46 3.03 -0.92 1.84 1.80 1.24 1.18 1.36 0.07 1.40 1.79
Interest & Investment Income		 2.73 3.03 3.20 2.58 1.66 0.99 0.58 1.00 1.28 0.95 1.13
Other Income / (Expense), net		 - - -4.12 -0.74 0.14 0.25 0.60 0.36 - 0.45 0.66
Basic Earnings per Share		 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21) ($0.39) ($0.16) ($0.20) ($0.17) ($0.22)
Weighted Average Basic Shares Outstanding		 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M 238.41M 260.49M 253.23M 276.86M 295.67M
Diluted Earnings per Share		 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21) ($0.39) ($0.16) ($0.20) ($0.17) ($0.22)
Weighted Average Diluted Shares Outstanding		 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M 238.41M 260.49M 253.23M 276.86M 295.67M
Weighted Average Basic & Diluted Shares Outstanding		 220.45M 221.50M 222.47M 223.27M 225.02M 225.56M 237.81M 266.37M 266.87M 278.29M 299.36M

Annual Cash Flow Statements for Sana Biotechnology

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 50 45 135 -75 -50 -5.95 -55
Net Cash From Operating Activities		 -86 -138 -251 -290 -254 -223 -144
Net Cash From Continuing Operating Activities		 -86 -138 -251 -290 -254 -223 -144
Net Income / (Loss) Continuing Operations		 -131 -285 -356 -269 -283 -267 -244
Consolidated Net Income / (Loss)		 -131 -285 -356 -269 -283 -267 -244
Depreciation Expense		 1.83 5.92 11 16 18 16 13
Non-Cash Adjustments To Reconcile Net Income		 21 10 26 41 43 38 68
Changes in Operating Assets and Liabilities, net		 23 131 68 -77 -30 -10 19
Net Cash From Investing Activities		 -88 -253 -246 211 172 17 -40
Net Cash From Continuing Investing Activities		 -88 -253 -246 211 172 17 -40
Purchase of Property, Plant & Equipment		 -26 -24 -30 -21 -20 -33 -0.94
Purchase of Investments		 -142 -387 -491 -79 -158 -226 -87
Sale of Property, Plant & Equipment		 - - - - 0.00 0.00 1.43
Sale and/or Maturity of Investments		 83 159 280 310 350 277 47
Net Cash From Financing Activities		 224 436 632 4.91 32 200 129
Net Cash From Continuing Financing Activities		 224 436 632 4.91 32 200 129
Issuance of Common Equity		 0.00 0.00 632 4.91 32 192 129
Other Financing Activities, net		 0.00 0.15 0.00 0.00 0.00 7.74 -0.35

Quarterly Cash Flow Statements for Sana Biotechnology

This table details how cash moves in and out of Sana Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -35 44 -42 -7.96 0.57 -31 -25 32 -31 12 -27
Net Cash From Operating Activities		 -52 -66 -59 -52 -47 -49 -33 -29 -33 -37 -33
Net Cash From Continuing Operating Activities		 -52 -66 -59 -52 -47 -49 -33 -29 -33 -37 -33
Net Income / (Loss) Continuing Operations		 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47 -64
Consolidated Net Income / (Loss)		 -88 -107 -50 -60 -49 -49 -94 -42 -59 -47 -64
Depreciation Expense		 11 3.75 3.90 4.06 5.69 3.65 2.86 3.19 3.05 2.39 2.23
Non-Cash Adjustments To Reconcile Net Income		 7.82 13 13 9.89 5.39 5.98 51 5.71 5.63 5.52 3.58
Changes in Operating Assets and Liabilities, net		 17 25 -26 -5.84 -9.18 -8.90 6.90 3.82 18 1.93 25
Net Cash From Investing Activities		 15 -77 5.82 42 47 17 7.68 -48 -16 49 -88
Net Cash From Continuing Investing Activities		 15 -77 5.82 42 47 17 7.68 -48 -16 49 -88
Purchase of Property, Plant & Equipment		 -14 -16 -13 -4.09 -0.44 -0.14 0.11 -0.04 -0.87 -0.29 -1.62
Purchase of Investments		 -26 -114 -63 -36 -13 -1.68 - -50 -36 -5.59 -102
Sale of Property, Plant & Equipment		 - 0.00 - - - 0.25 0.38 0.14 0.66 0.25 0.02
Sale and/or Maturity of Investments		 55 53 81 82 61 18 7.19 1.41 20 55 16
Net Cash From Financing Activities		 1.72 186 11 2.08 0.64 0.98 0.56 110 18 -0.13 94
Net Cash From Continuing Financing Activities		 1.72 186 11 2.08 0.64 1.07 0.59 109 18 -0.04 93
Issuance of Common Equity		 1.72 186 3.00 1.91 0.70 1.13 0.59 110 18 0.06 94

Annual Balance Sheets for Sana Biotechnology

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 730 1,129 823 565 501 417
Total Current Assets		 384 558 444 214 161 149
Cash & Equivalents		 125 253 177 134 128 72
Restricted Cash		 - 0.00 6.10 3.83 3.83 4.20
Short-Term Investments		 253 298 247 72 25 67
Prepaid Expenses		 6.20 7.11 14 4.49 4.48 6.10
Plant, Property, & Equipment, net		 47 65 67 71 77 27
Total Noncurrent Assets		 299 506 311 281 263 241
Goodwill		 141 141 141 141 141 141
Intangible Assets		 59 59 59 59 59 59
Other Noncurrent Operating Assets		 66 101 101 81 63 41
Total Liabilities & Shareholders' Equity		 730 1,129 823 565 501 417
Total Liabilities		 299 401 323 278 251 256
Total Current Liabilities		 31 99 112 64 45 79
Short-Term Debt		 - 51 55 0.00 0.00 40
Accounts Payable		 2.25 2.22 2.86 4.11 5.21 1.67
Accrued Expenses		 9.47 10 15 23 13 8.68
Current Employee Benefit Liabilities		 16 21 26 24 14 13
Other Current Liabilities		 3.71 14 12 13 13 15
Total Noncurrent Liabilities		 267 302 212 213 205 177
Capital Lease Obligations		 - 102 96 91 82 64
Other Noncurrent Operating Liabilities		 267 200 116 122 123 113
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -421 729 499 288 251 161
Total Preferred & Common Equity		 -421 729 499 288 251 161
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -421 729 499 288 251 161
Common Stock		 8.22 1,515 1,558 1,626 1,855 2,010
Retained Earnings		 -429 -785 -1,055 -1,338 -1,605 -1,849
Accumulated Other Comprehensive Income / (Loss)		 0.03 -1.37 -4.33 -0.06 0.01 0.03

Quarterly Balance Sheets for Sana Biotechnology

This table presents Sana Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 747 707 631 681 619 559 445 362 435 374 432
Total Current Assets		 370 339 280 321 263 210 113 83 162 112 171
Cash & Equivalents		 160 174 168 177 135 127 96 71 103 84 57
Restricted Cash		 6.10 6.10 3.83 3.83 3.83 3.83 4.20 4.20 4.20 4.20 4.20
Short-Term Investments		 189 152 100 134 117 72 8.57 1.40 50 17 103
Prepaid Expenses		 15 6.61 7.12 6.35 7.98 7.31 3.84 5.63 4.51 6.36 5.94
Plant, Property, & Equipment, net		 64 63 68 82 86 83 74 33 30 26 25
Total Noncurrent Assets		 313 306 284 278 269 266 259 246 244 236 236
Goodwill		 141 141 141 141 141 141 141 141 141 141 141
Intangible Assets		 59 59 59 59 59 59 59 59 59 59 59
Other Noncurrent Operating Assets		 103 106 84 79 69 67 59 46 44 36 36
Total Liabilities & Shareholders' Equity		 747 707 631 681 619 559 445 362 435 374 432
Total Liabilities		 319 352 266 306 279 267 236 239 240 254 277
Total Current Liabilities		 103 112 67 53 51 47 33 33 36 86 124
Short-Term Debt		 57 58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 54 91
Accounts Payable		 2.33 3.09 9.93 6.10 3.82 2.99 0.99 2.27 1.86 2.12 1.36
Accrued Expenses		 13 18 19 20 21 15 9.81 7.93 7.99 8.12 8.23
Current Employee Benefit Liabilities		 17 20 24 14 16 18 9.35 9.41 11 7.58 8.84
Other Current Liabilities		 13 13 13 13 10.00 11 13 14 14 15 15
Total Noncurrent Liabilities		 216 240 199 253 228 220 203 206 205 168 153
Capital Lease Obligations		 102 100 83 93 89 85 78 72 68 60 59
Other Noncurrent Operating Liabilities		 114 140 116 160 140 134 125 134 137 108 94
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 428 355 366 375 340 292 209 123 195 119 155
Total Preferred & Common Equity		 428 355 366 375 340 292 209 123 195 119 155
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 428 355 366 375 340 292 209 123 195 119 155
Common Stock		 1,567 1,607 1,616 1,821 1,836 1,848 1,863 1,871 1,985 2,015 2,114
Retained Earnings		 -1,137 -1,251 -1,250 -1,446 -1,496 -1,556 -1,654 -1,748 -1,790 -1,896 -1,960
Accumulated Other Comprehensive Income / (Loss)		 -2.14 -0.87 -0.20 -0.02 -0.02 0.05 0.00 0.00 0.02 -0.00 -0.07

Annual Metrics And Ratios for Sana Biotechnology

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - 266,366,120.00
DEI Adjusted Shares Outstanding		 - - - - - - 266,366,120.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.92
Growth Metrics		 - - - - - - -
Profitability Metrics		 - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -99 -200 -250 -191 -205 -191 -175
Return On Investment Capital (ROIC_SIMPLE)		 - - - -29.33% -54.23% -57.47% -66.12%
Earnings before Interest and Taxes (EBIT)		 -141 -286 -357 -273 -293 -277 -250
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -139 -280 -346 -258 -269 -260 -238
Valuation Ratios		 - - - - - - -
Leverage & Solvency		 - - - - - - -
Liquidity Ratios		 - - - - - - -
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -220 -356 -275 -164 -197 -122
Efficiency Ratios		 - - - - - - -
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 20 126 210 169 176 122
Increase / (Decrease) in Invested Capital		 0.00 20 106 84 -41 6.46 -53
Book Value per Share		 $0.00 ($32.36) $3.86 $2.62 $1.46 $1.12 $0.60
Tangible Book Value per Share		 $0.00 ($47.72) $2.80 $1.57 $0.44 $0.23 ($0.15)
Total Capital		 0.00 432 882 651 378 332 265
Total Debt		 0.00 0.00 153 151 91 82 104
Total Long-Term Debt		 0.00 0.00 102 96 91 82 64
Net Debt		 0.00 -412 -603 -289 -118 -75 -38
Capital Expenditures (CapEx)		 26 24 30 21 20 33 -0.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -25 -41 -42 -60 -41 -32
Debt-free Net Working Capital (DFNWC)		 0.00 353 510 388 149 115 110
Net Working Capital (NWC)		 0.00 353 459 333 149 115 70
Net Nonoperating Expense (NNE)		 32 85 106 79 78 76 69
Net Nonoperating Obligations (NNO)		 0.00 -412 -603 -289 -118 -75 -38
Total Depreciation and Amortization (D&A)		 1.83 5.92 11 16 25 17 13
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.14) ($1.43) ($1.46) ($1.16) ($0.96)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 189.54M 188.34M 194.54M 230.89M 253.23M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.14) ($1.43) ($1.46) ($1.16) ($0.96)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 189.54M 188.34M 194.54M 230.89M 253.23M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.14) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 166.43M 191.36M 220.45M 225.02M 266.87M
Normalized Net Operating Profit after Tax (NOPAT)		 -99 -200 -250 -191 -205 -191 -144
Debt Service Ratios		 - - - - - - -
Payout Ratios		 - - - - - - -

Quarterly Metrics And Ratios for Sana Biotechnology

This table displays calculated financial ratios and metrics derived from Sana Biotechnology's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 266,366,120.00 266,866,897.00 278,291,590.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 266,366,120.00 266,866,897.00 278,291,590.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -0.22 -0.18 -0.23
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Growth		 -1.92% -33.95% 55.69% -2,329.91% 43.25% 56.32% -84.52% 31.62% - 2.06% 31.68%
EBIT Growth		 -10.44% -31.48% 54.03% -3,228.17% 44.02% 54.50% -76.43% 30.96% - 4.41% 31.38%
NOPAT Growth		 -10.80% -31.73% 57.54% -1,882.24% 43.87% 54.27% -92.37% 29.54% - 3.98% 31.12%
Net Income Growth		 -9.54% -30.87% 55.88% -6,189.84% 44.31% 54.05% -86.51% 29.66% - 4.41% 32.16%
EPS Growth		 -4.76% -13.95% 64.41% 0.00% 52.27% 57.14% -85.71% 36.00% - 19.05% 43.59%
Operating Cash Flow Growth		 31.69% 17.21% 0.44% 18.46% 9.23% 25.86% 43.46% 43.21% - 23.18% 0.94%
Free Cash Flow Firm Growth		 84.19% 95.03% 47.50% -271.47% -87.73% -560.51% 56.68% 193.27% - 127.23% -516.18%
Invested Capital Growth		 -19.50% -30.84% -4.92% -0.96% 3.81% 16.55% -32.06% -39.51% - -28.34% 19.24%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Q/Q Growth		 -3,127.66% -34.54% 53.54% -17.84% 22.95% -3.78% -95.84% 56.33% - 21.28% -36.62%
EBIT Q/Q Growth		 -4,725.29% -21.95% 51.59% -16.84% 18.84% 0.68% -87.33% 54.27% - 21.30% -34.47%
NOPAT Q/Q Growth		 -2,808.45% -22.19% 55.41% -25.09% 17.64% 0.46% -87.59% 54.18% - 20.56% -34.57%
Net Income Q/Q Growth		 -9,054.98% -21.97% 53.21% -19.15% 18.11% -0.65% -89.92% 55.06% - 19.75% -34.79%
EPS Q/Q Growth		 0.00% -11.36% 57.14% -19.05% 16.00% 0.00% -85.71% 58.97% - 15.00% -29.41%
Operating Cash Flow Q/Q Growth		 18.24% -26.32% 10.80% 11.48% 8.99% -3.17% 31.97% 11.09% - -14.52% 12.28%
Free Cash Flow Firm Q/Q Growth		 -192.51% 58.93% -178.37% -62.12% -1.28% -44.51% 81.74% 449.07% - 56.60% -513.16%
Invested Capital Q/Q Growth		 -4.21% -9.58% 12.79% 1.38% 0.41% 1.51% -34.26% -9.73% - 4.48% 9.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Tax Burden Percent		 99.95% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Interest Burden Percent		 97.29% 97.25% 94.01% 95.87% 96.74% 98.03% 99.39% 97.68% - 98.03% 98.26%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Equity (ROE)		 -72.00% -76.82% -70.51% -92.90% -99.17% -71.44% -109.12% -96.11% - -147.41% -152.87%
Cash Return on Invested Capital (CROIC)		 -86.46% -83.06% -94.85% -123.33% -114.34% -105.04% -86.44% -70.30% - -80.44% -136.59%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Common Equity (ROCE)		 -72.00% -76.82% -70.51% -92.90% -99.17% -71.44% -109.12% -96.11% - -147.41% -152.87%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -82.26% -72.10% -104.56% 0.00% -99.81% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -63 -78 -35 -43 -36 -35 -66 -30 -43 -34 -46
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -12.13% -13.98% -9.25% -10.90% -13.97% -11.04% -31.74% -11.31% - -120.31% -179.76%
Return On Investment Capital (ROIC_SIMPLE)		 -16.76% - - - -10.72% -12.33% -34.23% -11.57% -16.17% -14.59% -15.03%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -91 -111 -53 -63 -51 -50 -94 -43 -61 -48 -65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -79 -107 -50 -58 -45 -47 -92 -40 -58 -46 -63
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.80 5.88 3.56 3.16 1.45 1.81 5.02 4.32 - 6.45 6.28
Price to Tangible Book Value (P/TBV)		 9.17 12.57 8.65 9.99 7.18 40.84 0.00 0.00 - 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.05 12.94 6.04 4.61 1.65 1.95 5.20 7.13 - 6.08 6.84
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.32 0.25 0.26 0.29 0.33 0.37 0.58 0.35 - 0.96 0.97
Long-Term Debt to Equity		 0.32 0.25 0.26 0.29 0.33 0.37 0.58 0.35 - 0.51 0.38
Financial Leverage		 -0.52 -0.53 -0.49 -0.47 -0.36 -0.43 -0.37 -0.42 - -0.07 -0.07
Leverage Ratio		 1.76 1.78 1.91 1.81 1.98 1.93 2.12 2.04 - 2.49 2.86
Compound Leverage Factor		 1.72 1.73 1.79 1.73 1.92 1.89 2.11 1.99 - 2.45 2.81
Debt to Total Capital		 24.02% 19.85% 20.68% 22.62% 24.58% 27.25% 36.90% 25.79% - 48.88% 49.26%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 22.96% 29.81%
Long-Term Debt to Total Capital		 24.02% 19.85% 20.68% 22.62% 24.58% 27.25% 36.90% 25.79% - 25.92% 19.45%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 75.98% 80.15% 79.32% 77.38% 75.42% 72.75% 63.10% 74.21% - 51.12% 50.74%
Debt to EBITDA		 -0.34 -0.31 -0.39 -0.30 -0.31 -0.40 -0.30 -0.30 - -0.48 -0.72
Net Debt to EBITDA		 0.44 0.75 0.73 0.41 0.29 0.16 0.02 0.40 - -0.04 0.07
Long-Term Debt to EBITDA		 -0.34 -0.31 -0.39 -0.30 -0.31 -0.40 -0.30 -0.30 - -0.26 -0.28
Debt to NOPAT		 -0.44 -0.42 -0.50 -0.39 -0.43 -0.53 -0.40 -0.40 - -0.66 -0.98
Net Debt to NOPAT		 0.58 0.99 0.94 0.54 0.39 0.21 0.03 0.53 - -0.05 0.10
Long-Term Debt to NOPAT		 -0.44 -0.42 -0.50 -0.39 -0.43 -0.53 -0.40 -0.40 - -0.35 -0.39
Altman Z-Score		 -1.79 1.29 -0.66 -1.83 -3.67 -4.40 -5.92 -3.63 - -5.64 -4.62
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.31 6.07 5.20 4.47 3.54 3.40 2.47 4.55 - 1.29 1.38
Quick Ratio		 3.18 5.88 4.96 4.23 3.36 3.16 2.17 4.31 - 1.17 1.30
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -22 -9.20 -26 -42 -42 -61 -11 39 11 17 -68
Operating Cash Flow to CapEx		 -369.92% -414.21% -448.38% -1,266.04% -10,816.74% 0.00% 0.00% 0.00% - -93,447.50% -2,051.94%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 169 153 173 175 176 178 117 106 122 128 140
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Increase / (Decrease) in Invested Capital		 -41 -68 -8.94 -1.70 6.46 25 -55 -69 -53 -51 23
Enterprise Value (EV)		 686 1,982 1,042 808 289 347 611 755 - 777 957
Market Capitalization		 804 2,204 1,209 925 364 378 616 844 - 769 971
Book Value per Share		 $1.46 $1.70 $1.53 $1.31 $1.12 $0.93 $0.54 $0.82 $0.60 $0.45 $0.56
Tangible Book Value per Share		 $0.44 $0.80 $0.63 $0.42 $0.23 $0.04 ($0.34) ($0.02) ($0.15) ($0.30) ($0.16)
Total Capital		 378 468 428 378 332 287 194 263 265 233 305
Total Debt		 91 93 89 85 82 78 72 68 104 114 150
Total Long-Term Debt		 91 93 89 85 82 78 72 68 64 60 59
Net Debt		 -118 -222 -167 -117 -75 -31 -5.21 -89 -38 8.68 -15
Capital Expenditures (CapEx)		 14 16 13 4.09 0.44 -0.12 -0.49 -0.10 0.21 0.04 1.60
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -60 -47 -43 -40 -41 -29 -28 -31 -32 -26 -27
Debt-free Net Working Capital (DFNWC)		 149 268 213 163 115 80 49 126 110 79 138
Net Working Capital (NWC)		 149 268 213 163 115 80 49 126 70 25 47
Net Nonoperating Expense (NNE)		 25 30 16 17 13 14 27 12 16 13 18
Net Nonoperating Obligations (NNO)		 -118 -222 -167 -117 -75 -31 -5.21 -89 -38 8.68 -15
Total Depreciation and Amortization (D&A)		 11 3.75 3.90 4.06 5.69 3.65 2.86 3.19 3.05 2.39 2.23
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21) ($0.39) ($0.16) ($0.20) ($0.17) ($0.22)
Adjusted Weighted Average Basic Shares Outstanding		 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M 238.41M 260.49M 253.23M 276.86M 295.67M
Adjusted Diluted Earnings per Share		 ($0.44) ($0.49) ($0.21) ($0.25) ($0.21) ($0.21) ($0.39) ($0.16) ($0.20) ($0.17) ($0.22)
Adjusted Weighted Average Diluted Shares Outstanding		 194.54M 217.29M 234.44M 235.41M 230.89M 237.58M 238.41M 260.49M 253.23M 276.86M 295.67M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 220.45M 221.50M 222.47M 223.27M 225.02M 225.56M 237.81M 266.37M 266.87M 278.29M 299.36M
Normalized Net Operating Profit after Tax (NOPAT)		 -63 -78 -35 -43 -36 -35 -35 -30 -43 -34 -46
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Sana Biotechnology remains a development-stage company with no reported revenue in the periods provided. Its financial profile is therefore driven primarily by research spending, cash consumption, equity financing and the value of its investment portfolio rather than operating sales.

Liquidity has improved from the first quarter of 2026, but the longer-term trend is weaker. As of June 30, 2026, Sana reported $57.1 million in cash and equivalents, $4.2 million in restricted cash and $103.4 million in short-term investments, giving it approximately $164.3 million in cash and near-cash resources. Total current assets were $170.6 million compared with $123.8 million of current liabilities, a current ratio of roughly 1.4. However, total assets have declined from $618.7 million in the second quarter of 2024 and $707.1 million in the second quarter of 2023.

The company continues to operate at a substantial loss. Second-quarter 2026 net loss was $63.6 million, or $0.22 per share, compared with a $47.2 million loss, or $0.17 per share, in the first quarter. The latest loss was still lower than the restated $93.8 million loss recorded in the second quarter of 2025, but there is no clear path to profitability in the supplied data.

  • Operating cash burn moderated versus earlier periods. Second-quarter 2026 cash used in operating activities was $32.8 million, down from $48.7 million in the first quarter of 2025 and $65.6 million in the first quarter of 2024. It was also slightly below the $37.4 million used in the first quarter of 2026.
  • Cash and investment resources remain meaningful. Sana held approximately $164.3 million in cash, restricted cash and short-term investments at the end of the second quarter of 2026, providing financial flexibility for continued research and development.
  • Equity financing replenished liquidity in the latest quarter. The company raised approximately $93.6 million through financing activities in the second quarter of 2026, primarily through common-stock issuance. This helped offset operating and investing cash outflows.
  • Interest and investment income provides a modest offset to losses. Sana generated $1.8 million of total other income in the second quarter of 2026, including $1.1 million of interest and investment income.
  • Investment activity is materially affecting cash balances. Sana purchased $101.7 million of investments and received $15.8 million from investment maturities or sales in the second quarter. These transactions appear to reflect portfolio management rather than operating growth, so quarterly cash changes may remain volatile.
  • Book value improved sequentially but remains vulnerable to continued losses. Total shareholders’ equity increased from $119.2 million in the first quarter of 2026 to $154.6 million in the second quarter, largely reflecting the equity financing. Retained earnings, however, remained deeply negative at approximately $2.0 billion.
  • Sana has reported no revenue in the supplied quarters. With revenue and gross profit at zero throughout the available periods, the company currently lacks operating income to fund research spending.
  • Research and development spending accelerated in the latest quarter. R&D expense increased to $54.6 million in the second quarter of 2026 from $37.2 million in the first quarter, pushing total operating expenses to $65.4 million from $48.6 million.
  • Losses remain persistent and cash flow remains negative. Sana recorded negative operating cash flow in every supplied quarter from the third quarter of 2022 through the second quarter of 2026, while retained earnings continued to deteriorate.
  • Shareholder dilution and obligations are increasing. Weighted-average basic shares rose to 295.7 million in the second quarter of 2026 from 189.3 million in the third quarter of 2022. The company also reported $90.8 million of short-term debt and $59.2 million of capital lease obligations at June 30, 2026, creating additional claims on its liquidity.

Overall, Sana’s balance sheet provides a limited cushion for continued development, and recent equity financing reduced near-term liquidity pressure. Nevertheless, the investment case remains highly dependent on clinical and commercial progress because the company has no reported revenue, continues to consume cash and has increasingly relied on issuing shares to fund operations.

09/14/26 08:51 PM ETAI Generated. May Contain Errors.

Sana Biotechnology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sana Biotechnology's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Sana Biotechnology's net income appears to be on an upward trend, with a most recent value of -$244.17 million in 2025, rising from -$130.78 million in 2019. The previous period was -$266.76 million in 2024. See Sana Biotechnology's forecast for analyst expectations on what's next for the company.

Sana Biotechnology's total operating income in 2025 was -$250.32 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $250.32 million

Over the last 6 years, Sana Biotechnology's total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

Sana Biotechnology's total liabilities were at $256.01 million at the end of 2025, a 2.2% increase from 2024, and a 14.3% decrease since 2020.

In the past 5 years, Sana Biotechnology's cash and equivalents has ranged from $71.87 million in 2025 to $253.03 million in 2021, and is currently $71.87 million as of their latest financial filing in 2025.

Over the last 6 years, Sana Biotechnology's book value per share changed from 0.00 in 2019 to 0.60 in 2025, a change of 60.4%.


Related Companies

Financial statements for NASDAQ:SANA last updated on 8/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
BlackRock and Vanguard already own THIS
Institutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...
Monument Traders Alliance | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Jon Najarian's #1 Energy Trade for 2026
Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...
Banyan Hill Publishing | Sponsoredtc pixel
Gold majors have a big problem
Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...
Golden Portfolio | Sponsoredtc pixel
Gold just passed our debt as the world's #1 asset
China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...
Behind the Markets | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Elon Musk’s Hushed FCC Filing. Sept 25th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...
Paradigm Press | Sponsoredtc pixel